Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 4/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584557 | 0.86 | DDB1 (0.37) | DDB1CRBNKMT2AMEN1KDM4E | |
| SCHEMBL3593976 | 0.82 | CREBBP (0.34) | DDB1CRBNKDM4EALDH1A1GAA | |
| SCHEMBL3597334 | 0.81 | DDB1 (0.35) | DDB1CRBNKMT2AMEN1KDM4E | |
| SCHEMBL3595539 | 0.77 | HSP90AA1 (0.36) | KMT2AMEN1KDM4EALDH1A1HTT | |
| SCHEMBL3589696 | 0.76 | DDB1 (0.33) | DDB1CRBNKMT2AMEN1GAA | |
| SCHEMBL3597784 | 0.76 | PDE3B (0.36) | DDB1CRBNGAAMAPTPARP1 | |
| SCHEMBL3598948 | 0.75 | HTR1A (0.34) | DDB1CRBNKDM4EALDH1A1GAA | |
| SCHEMBL3592385 | 0.74 | TRPV1 (0.38) | DDB1CRBNKDM4EALDH1A1HTT | |
| SCHEMBL3590434 | 0.72 | TRPV1 (0.41) | DDB1CRBNKDM4EALDH1A1TSHR | |
| SCHEMBL3597785 | 0.71 | PDE3B (0.36) | DDB1CRBNALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | DDB1 1855/4885CRBN 762/4885KMT2A 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.